Comparative Pharmacology
Head-to-head clinical analysis: CALAN SR versus DILACOR XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALAN SR versus DILACOR XR.
CALAN SR vs DILACOR XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
Oral: 180–240 mg once daily; maximum 480 mg/day.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours (average ~8 hours) after single oral dose; may increase to 12-16 hours with chronic dosing due to saturable hepatic metabolism; clinical context: requires dosing adjustments in hepatic impairment.
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Approximately 70% of the dose is excreted as metabolites in the urine; 3-4% as unchanged drug; 25% eliminated in feces via biliary excretion.
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker